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Use of MicroRNA Expression Levels to Predict Outcomes in
Resected Stage I Non-small Cell Lung Cancer
Eric Duncavage, MD,* Boone Goodgame, MD,†‡ Ananth Sezhiyan, BS,†
Ramaswamy Govindan, MD,†‡ and John Pfeifer, MD, PhD‡§
Background: Despite undergoing curative resection, nearly a third of
patients with stage I non-small cell lung cancer (NSCLC) die of
recurrent disease. There are no reliable clinical or molecular predictors
of relapse in patients with resected stage I NSCLC. Identifying patients
at risk for relapse after surgical resection is one of the important
challenges today. MicroRNAs (miRNAs) regulate hundreds of genes
central to maintaining a cancer phenotype.
Methods: In an exploratory study, we determined whether expres-
sion of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and
miR-221) previously reported to correlate with invasiveness or
outcome in various human malignancies were associated with tumor
recurrence in patients with resected stage I NSCLC. We measured
expression of these miRNAs in formalin-fixed, paraffin-embedded
tissue from both tumor and matched normal lung in a set of 46
patients with surgically resected T1 or T2 stage I NSCLC.
Results: Averaged triplicate data showed that tumors which
recurred had 0.14-fold lower miR-221 expression than those
which did not recur (p  0.0036). In addition, increased miR-
221in tumor tissue when compared with adjacent normal appear-
ing lung in the same patient also correlated with nonrecurrence
(p  0.0011). Parallel measurement of expression of selected
downstream target genes regulated by miR-221, specifically,
CDKN1B, CDKN1C, paralemmin-2, and CXCL12, showed a near
significant (p  0.0522) down-regulation of CDKN1C in tumors
of patients with no recurrent disease, consistent with increased
miR-221 activity in the same group.
Conclusion: If confirmed in prospective studies, miRNA expression
in resected NSCLC could potentially identify those at high risk of
relapse after surgery.
Key Words: Non-small cell lung cancer, miR-7, miR-221, miR-155,
miR-21, let7a, miR-210, MicroRNA, Recurrence, Prognosis, Stage I.
(J Thorac Oncol. 2010;5: 1755–1763)
Lung cancer remains the leading cause of cancer relateddeath in both men and women in the United States and
worldwide. It is projected that more than 200,000 people will
be diagnosed with lung cancer in 2010 in the United States,
and more than 80% will eventually die as a result of the
disease.1,2 Approximately 22% patients with non-small cell
lung cancer (NSCLC) present with stage I disease, which is
usually treated with surgical resection.3 Nevertheless, about
one third of patients who undergo resection for stage I
NSCLC will eventually have a recurrence.4 Adjuvant chemo-
therapy in resected stage II and stage III NSCLC improves
survival but has not been shown to have a benefit in uns-
elected patients with stage I disease.5–8 The lack of survival
benefit in the limited number of studies that included stage I
patients has generally, and perhaps correctly, been attributed
to the combination of smaller sample size, lower event rate
(relapse), and the modest effect of systemic therapy. Two
unplanned subset analysis from prospective studies suggest
that there is probably a modest benefit in overall survival in
patients with larger tumors (those measuring 4 cm or
more).9,10 There is clearly an urgent need to develop molec-
ular markers that would reliably identify those at high risk for
relapse after surgery for stage I NSCLC.
Global gene expression analysis using microarray tech-
nology has been used extensively in an attempt to classify
disease recurrence risk, but none of the system has proven
robust enough for clinical use.11–15 In addition, array cost and
the difficulty in procuring frozen tissue for analysis limit the
utility of such assays in routine clinical practice.16
MicroRNAs (miRNAs) are a recently described class of
small (20 nt) noncoding RNAs that regulate gene expres-
sion.17,18 Mammalian miRNAs are generally encoded in in-
trons or the 3 untranslated region of mRNA. After nuclear
processing, pre-miRNAs are transported to the cytosol where
they are cleaved and activated by the Dicer complex. Once
activated, miRNAs reduce gene expression by binding to
complementary regions of mRNA, blocking translation, or by
degrading mRNA through the argonaut complex.18,19 Be-
cause each miRNA species has the ability to regulate multiple
genes, miRNAs are attractive markers for studies of coordi-
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nated gene expression. Unlike global gene expression studies
using microarrays, it has been relatively easy to study the
expression of miRNA in archived formalin-fixed paraffin-
embedded specimens. Compared with mRNA transcripts that
are often 1 kb, the small size of miRNAs limits the amount
of formalin fixation-induced cross-linking, resulting in FFPE
miRNA expression levels similar to those in fresh-frozen
tissue.20 If validated in appropriately conducted prospective
studies, miRNA expression assay would be a readily appli-
cable and useful in the clinic where FFPE tissue blocks are
widely available but prospectively collected frozen tissue for
mRNA analysis is not.
Of more than 700 known miRNAs, we selected six
miRNAs for this pilot study. The primary objective of this
pilot study was to demonstrate the feasibility of using miRNA
expression levels to predict outcomes in early-stage NSCLC.
These miRNAs (miR-7, let7a, miR-21, miR-155, miR-210,
and miR-221) were chosen based on their known associations
with outcome, survival, or invasiveness in lung cancer or
other carcinomas (Table 1). We measured the expression of
these miRNAs in formalin-fixed, paraffin-embedded tissue
from both tumor and matched adjacent normal appearing lung
tissues in a set of patients with surgically resected stage I
NSCLC. We also measured the expression levels of selected
downstream target genes regulated by one of the miRNAs,




Patients were selected from the thoracic oncology da-
tabase at the Alvin J Siteman Cancer Center at Washington
University School of Medicine in St. Louis, which includes
consecutive patients who underwent resection for stage I
NSCLC between 1990 and 2005. Details regarding treatment
and follow-up procedures have been published previously.4
In this larger dataset, we identified a cohort of patients with
adequate tumor specimens who had either recurrence of lung
cancer or greater than 3 years of follow-up without recur-
rence. From this group, 46 patients were chosen at random for
our initial exploratory study. None of the 46 patients received
any postoperative therapy. All the relevant pathology slides
were reviewed by at least one of the study authors (E.D. and
J.P.) to identify areas of adequate tumor cellularity and
adjacent normal appearing lung tissue. This study was ap-
proved by the Human Studies Committee at Washington
University School of Medicine.
RNA Extraction
For each case, hematoxylin and eosin-stained slides
were used to identify areas containing at least 70% tumor
nuclei with minimal necrosis. Areas of nonneoplastic normal
appearing lung (at least 1 cm from the tumor) were similarly
selected. The slides and blocks were aligned, and the neo-
plastic and nonneoplastic areas were punched with sterile,
single-use 1-mm punches (Miltex, Tuttlingen, Germany).32
RNA was then extracted from the tissue cores using standard
techniques.33 Briefly, the tissue cores were deparaffinized,
dissociated by a sterile micropestel, digested for 8 hours at
55°C with proteinase K, and finally RNA extracted with the
Ambion RecoverAll kit (Applied Biosystems, Austin, TX).
The recovered RNA was DNAse treated and quantitated by
spectrophotometer.
Quantitative (Real Time) Polymerase Chain
Reaction for miRNA Expression
Approximately 10 ng of RNA was converted to com-
plementary DNA (cDNA) using the ABI miRNA reverse
transcription kit (Applied Biosystems, Foster City, CA) and
miRNA-specific primers (Applied Biosystems, Foster City,
CA) (for miR-7, let7a, miR-21, miR-155, miR-210, and
miR-221). After reverse transcription, quantitative polymer-
ase chain reaction (PCR) was performed in triplicate for each
tumor sample and each paired normal lung sample on an ABI
7500 Fast thermocycler (Applied Biosystems, Foster City,
CA). Specifically, for each miRNA, approximately 0.2 ng
cDNA of patient and 10 L of Universal PCR Master Mix
without AmpErase UNG (Applied Biosystems, Foster City,
CA) was added to commercially available PCR primers and
FAM-labeled TaqMan probes (Applied Biosystems, Foster
City, CA). The housekeeping miRNA rnu-6b was used as a
normalization control for all tumor and normal lung patient
samples.
TABLE 1. Supporting Evidence for Selected MicroRNAs
MicroRNA Association References
let-7a Decreased expression associated with
poor survival in lung
adenocarcinoma
21
Functionally inhibits non-small cell
tumor development
22
Increased expression associated with
survival in lung cancer
23
miR-7 Increased expression associated with
aggressive breast cancer
24
Inhibits EGFR signaling 25
miR-21 Promotes cancer growth in vitro 26
Increased expression in sputum of
patients with lung cancer
27
Overexpression associated with poor
overall survival in NSCLC
28
miR-155 Increased expression associated with
poor survival in lung
adneocarcinoma
21
miR-210 Increased expression associated with
aggressive breast cancer
24
Induced by hypoxia and associated
with adverse overall survival in
breast cancer
29
miR-221 Increased expression associated with
survival in lung cancer
23
Reduced expression associated with
prostate cancer recurrence and
metastasis
30, 31
NSCLC, non-small cell lung cancer.
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Quantitative (Real Time) PCR of mRNA for
miRNA Target Genes
Approximately 100 ng of RNA was converted into
cDNA using the ABI High Capacity Reverse Transcription
kit (Applied Biosystems, Foster City, CA) and random oli-
gonucleotide primers. After reverse transcription, quantitative
PCR was performed in triplicate for each tumor sample and
each paired normal lung sample using gene-specific primers
and FAM-labeled TaqMan Probes (Applied Biosystems, Fos-
ter City, CA). Gene expression was normalized to a multi-
plexed beta-actin control using VIC/TAMRA-labeled Taq-
Man probes.
Data Analysis
Expression Ct values were obtained from the ABI 7500
Fast thermocycler using the supplied software and the “au-
tomatic analysis” function to ensure plate to plate consis-
tency. Triplicate Ct values for both tumor samples and
matched nonneoplastic lung samples were normalized to
rnu-6b expression for miRNA expression and the multiplexed
beta actin control for gene expression. The normalized values
were averaged and then analyzed with GraphPad Prism
(GraphPad, La Jolla, CA) and the R Statistical l package.
Statistical Analysis
To account for differences in variance between the
recurrent and nonrecurrent disease groups and to reduce the
effects of outliers, a nonparametric Mann-Whitney U test was
used to determine significance. An unpaired U test was used
to compare expression of each miRNA to tumor recurrence
individually, whereas a paired U test was used to compare
miRNA expression in tumor and paired nonneoplastic lung
samples. p values of 0.05 were deemed significant. Finally,
to account for multiple miRNAs acting in concert, a multi-
variate Hotelling T2 test was used within the R statistical
package.
RESULTS
The clinical characteristics of the 46 patients included
in this study were typical of the demographics of NSCLC
reported in the United States with respect to age, gender, and
histology. Twenty-four patients had no tumor recurrence, and
22 had recurrent disease. Baseline clinical and pathologic
characteristics were similar in those with and without recur-
rence with the exception that more patients with relapse had
adenocarcinoma histology (73%), when compared with those
without relapse (33%, p 0.008) (Figure 1 and Table 2). The
median duration of follow-up was 3.4 years in all patients and
4.7 years in those without evidence of recurrence. For those
patients who developed recurrent NSCLC, the median time to
diagnosis of relapse was 1.7 years.
Adequate RNA for analysis was extracted for each
case, and each miRNA was successfully quantified by PCR
for each case. Expression levels for each miRNA were
FIGURE 1. Cases of stage I non-small cell carci-
noma included predominantly squamous cell car-
cinomas (A) and adenocarcinomas of the lung (B)
(100 original magnification). RNA was extracted
from areas of tumor that contained greater than
70% tumor nuclei and minimal necrosis.




pN Percentage N Percentage
Total subjects 24 22
Age (median) 65 67 0.321
Gender 0.382
Male 10 42 12 55
Female 14 58 10 45
Race 0.101
White 19 79 21 95
Black 4 17 1 5
Other 1 4 0 0
T status 0.369
T1 13 54 9 41
T2 11 46 13 59
Tumor size (median) 2.6 3.5 0.107
Tumor histology 0.008
Adenocarcinoma 8 33 16 73
Squamous 14 58 4 18
Other 2 8 2 9
Grade of differentiation 0.322
1 2 8 4 18
2 11 46 8 36
3 11 46 10 45
Surgical treatment 0.134
Wedge or segmental 2 8 0 0
Lobectomy 22 92 20 91
Pneumonectomy 0 0 2 9
NSCLC, non-small cell lung cancer.
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normalized to the housekeeping miRNA rnu-6b, with results
for each case shown in Figure 2. Levels of expression for
each miRNA were then compared between recurrent and
nonrecurrent cases. We found a statistically significant cor-
relation between tumor recurrence and the expression levels
of one of the six tested miRNAs, miRNA-221. The mean
expression level of miRNA-221 in cases where there was
recurrence was 0.14-fold lower than cases without recurrence
FIGURE 2. Expression of averaged triplicate microRNA (miRNA) data normalized to rnu-6b (log plots).
FIGURE 3. Kaplan-Meier freedom-from-
recurrence curves for miR-221 expression.
miR-221 values were first dichotomized
about a mean expression value and those
cases with expression above the mean value
designated “high expression” and those be-
low designated “low expression.”
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(p  0.0036). When the cases were grouped by miR-221
expression (greater or less than the mean), a Kaplan-Meier
analysis for recurrence showed a modest but not statistically
significant, reduced risk of recurrent disease for cases with
high-miR-221 expression (Figure 3).
Expression levels of two other miRNAs, miR-155 and
miR-7, showed a trend toward significant correlation. The
remaining miRNAs did not show a discernable difference in
expression between patients with or without recurrent dis-
ease. Multivariate testing by Hotelling T2 revealed a signifi-
cant difference (p  0.030) in the mean expression vectors
for recurrent versus nonrecurrent tumors, implying that use of
all six miRNAs together differentiated between recurrent and
nonrecurrent tumors.
As a disproportionate number of patients with adeno-
carcinoma developed recurrent disease compared with the
other histologic types, we compared the expression levels of
miR-221 with outcome by histology. We could not perform a
robust multivariate analysis because of the very small sample
size. Nevertheless, we compared miR-221 expression by
recurrence status in both histologic groups. We found that
mean expression levels were lower in recurrent patients for
both adenocarcinoma (0.80) and squamous cell carcinoma
(0.70) (Figure 4). These trends were not statistically signifi-
cant, likely because of small sample size.
We also compared the expression levels for each
miRNA in the malignant tissues with that in the normal
appearing lung tissues. This allowed us to determine whether
variations in endogenous miRNA expression levels affected
the data and to determine whether alterations in miRNA
expression may be associated with the malignant phenotype.
For those miRNAs in which expression levels correlated with
recurrence as described earlier (miR-221, 155, and 7), the
relative changes in expression between tumor and normal
correlated with the absolute levels in the tumors. For exam-
ple, in nonrecurrent tumors, miR-221 expression was 2.5-fold
higher in the malignant tissue, when compared with adjacent
normal lung (p  0.0011); an association not seen in the
recurrent tumors. Similarly, in recurrent tumors, miR-155
expression was increased to 3.9-fold, when compared with
normal lung (p  0.0080), and miR-7 expression was signif-
icantly decreased by 0.11-fold (p  0.0027) (Figure 5).
To further determine the significance of miR-221 in
stage I NSCLC, we measured the expression of four genes,
CDKN1B, CDKN1C, CXCL12, and PALM2, that have either
been experimentally demonstrated or computationally pre-
dicted to be regulated by miR-221. Both CDKN1B and
CDKN1C (p57Kip2) have been experimentally shown to be
attenuated by miR-221 in various tissue types.34,35 Both
PALM2, implicated in cell membrane dynamics, and CXCL12
(SDF1), a chemoattractant, are computationally predicted to
be bound and regulated by miR-221.36–38 We found a near
significant 2.5-fold reduction (p  0.052) in CDKN1B ex-
pression between recurrent and nonrecurrent tumors (Figure
6); however, an evaluation of the protein level expression of
CDKN1B would be necessary to confirm the significance of
this finding. The remaining three genes showed no relation-
ship to disease recurrence.
FIGURE 4. MiR-221 expression by recurrence status in adenocarcinoma (A) and squamous cell carcinoma (B).
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DISCUSSION
We have shown in this exploratory study that expres-
sion levels of select miRNAs in paraffin-embedded tumor
tissue may be able to provide prognostic information for
patients with stage I NSCLC. More specifically, down-regu-
lation of miR-221 strongly correlated with recurrence. We
also found that the relative miRNA expression in the tumor,
when compared with paired normal lung correlated with
outcome.
Although increased expression of miR-221 has gener-
ally been associated with aggressive features in hepatocellu-
lar carcinoma39 and cancer cell proliferation,40 in this study,
we actually found better outcomes in patients with resected
stage I NSCLC with increased expression of miR-221. Al-
though these findings seem somewhat contradictory, similar
findings have been reported with prostate cancer and lung
cancer. Reduced miR-221 expression has been associated
with prostate cancer recurrence and metastasis.30,31,41 This
apparent contradiction may be partially explained by the
tissue-specific association of miRNAs and the apparent du-
ality of CDKN1B function, which can act as both a tumor
suppressor, through inhibition of Cdk2, or as an oncogene,
through unknown mechanisms.42,43 Also, increased miR-221
was associated with decreased CDKN1B. It is interesting to
note that in CDKN1B knock-in mice that express a mutant
form of the protein which is unable to inhibit cyclin-CDK
complex formation, lung tumors are a common phenotype.44
This argues that in lung tumors, the oncogenic effect of
increased CDKN1B contributes to cancer development,
whereas in tumors of other organ systems, loss of the tumor
suppressive role of CDKN1B may be important.
Two studies were published recently that correlated
miRNA expression with outcomes in NSCLC using mi-
croarray hybridization technology. In the first study, 752
miRNAs were evaluated in 77 cases, 37 with recurrence
and 40 without recurrence.45 The most accurate classifiers
for recurrence were miR-200b, miR-30c-1, miR-510, miR-
630, miR-124, and miR-585. In the second study, 290
cases of resected NSCLC, including 117 with stage I
disease, were evaluated on a customized oligonucleotide
array, using 440 known miRNAs.46 Markedly different
miRNA expression profiles were observed between adeno-
FIGURE 5. A comparison of microRNA
(miRNA) expression in tumor (red) and
paired, adjacent normal lung (blue) for both
nonrecurrent tumors (left panel) and recur-
rent tumors (right panel).
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FIGURE 6. Expression of selected miR-221 target genes. Target gene expression was normalized to a multiplexed beta-
actin control.
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carcinoma and squamous cell carcinoma. Interestingly, for
adenocarcinoma, no miRNAs were associated with sur-
vival other than what would be expected by random
chance. Nevertheless, for squamous cell carcinoma, five
miRNAs (miR-25, miR-34c-5p, miR-191, let-7e, and miR-
34a) strongly predicted survival. Two additional miRNAs
(miR-638 and miR-107) were evaluated by PCR in the
cases with squamous cell carcinoma and had an association
with survival. Interestingly, miR-221, which was found to
be significant in our study, did not correlate with outcome
in these array-based studies.
Unlike the two studies cited earlier,21,28 we used paired
normal lung tissue to normalize miRNA expression as dis-
cussed previously. The use of tumor and adjacent uninvolved
normal appearing tissues for determining the relative expres-
sion of miRNAs has some advantages. miRNA expression
levels and functions can vary widely among various tissues
types, and furthermore, this approach would limit the vari-
ability caused by differences in tissue preservation and qual-
ity of extracted nucleic acids. In our study, normalization
between malignant and normal appearing tissues uncovered
statistically significant correlations between miRNA expres-
sion and outcome that were not apparent until tumor tissue
was compared with normal appearing tissue. Although these
studies differ broadly with respect to sample size, design, and
technology, all three studies together suggest the potential
usefulness of miRNAs in predicting outcomes in patients
with resected NSCLC. Naturally, the extremely small sample
size and the limited number of hand-picked miRNAs studied
in this study demonstrate, at best, only the potential value of
using miRNA expression levels in predicting outcomes in
patients with early-stage NSCLC after resection.
Moving forward, we believe a larger panel of miRNAs
would need to be evaluated in an uniform cohort of patients
with one histologic subtype of NSCLC, treated with only
surgery, to determine whether miRNA expression levels
would predict overall survival. The initial results should be
further validated in a similar but an independent prospective
study. The fact that miRNA expression levels can be deter-
mined using formalin-fixed paraffin-embedded specimens al-
lows immediate and widespread use in the clinic if these
results are confirmed.
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